<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04307381</url>
  </required_header>
  <id_info>
    <org_study_id>ISIS 721744-CS3</org_study_id>
    <secondary_id>2020-000197-14</secondary_id>
    <nct_id>NCT04307381</nct_id>
  </id_info>
  <brief_title>An Extension Study of IONIS-PKK-LRx in Participants With Hereditary Angioedema</brief_title>
  <official_title>An Open-Label Extension Study of ISIS 721744 in Patients With Hereditary Angioedema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ionis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of extended dosing of&#xD;
      IONIS-PKK-LRx administered subcutaneously (SC), with alternative dosing and/or dose frequency&#xD;
      with IONIS-PKK-LRx in participants with hereditary angioedema (HAE).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label extension study of IONIS-PKK-LRx in up to 24 participants with HAE. The&#xD;
      length of participation in the study is approximately 68 weeks, which includes an up to&#xD;
      4-week qualification period, a 52-week treatment period, and a 12-week post-treatment period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with at Least One Treatment-emergent Adverse Event (TEAE), Graded by Severity</measure>
    <time_frame>Up to Week 65</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Time-normalized HAE Attacks (per Month) by Treatment</measure>
    <time_frame>Up to Week 65</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Prekallikrein (PKK) Levels</measure>
    <time_frame>Up to Week 65</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Proenzyme Activation</measure>
    <time_frame>Up to Week 65</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Cleaved High Molecular Weight Kininogen (cHK) Level</measure>
    <time_frame>Up to Week 65</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consumption of On-demand Medications</measure>
    <time_frame>Up to Week 65</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angioedema Quality of Life (AE-QoL) Questionnaire Score</measure>
    <time_frame>Up to Week 65</time_frame>
    <description>The AE-QoL was developed to measure health-related quality of life (HRQoL) impairment in participants with recurrent angioedema. The AE-QoL is a self-administered questionnaire that can be completed in less than 5 minutes. It comprises 17 items across 4 domains: functioning, fatigue/mood, fears/shame, and food. Responses use a 5-point Likert scale ranging from 'never' to 'very often.' Global and domain scores range from 0 to 100, with higher scores indicating greater impairment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Hereditary Angioedema</condition>
  <arm_group>
    <arm_group_label>IONIS-PKK-LRx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered IONIS-PKK-LRx SC for up to 52 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IONIS-PKK-LRx</intervention_name>
    <description>IONIS-PKK-LRx administered SC</description>
    <arm_group_label>IONIS-PKK-LRx</arm_group_label>
    <other_name>ISIS 721744</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Satisfactory completion of ISIS 721744-CS2 (index study) through Week 17 with an&#xD;
             acceptable safety and tolerability profile, per Sponsor and Investigator judgement&#xD;
&#xD;
          2. Able and willing to participate in a 64-week study&#xD;
&#xD;
          3. Females must be non-pregnant, non-lactating and either surgically sterile or&#xD;
             post-menopausal&#xD;
&#xD;
          4. Males must be surgically sterile or abstinent* or if engaged in sexual relations with&#xD;
             a female of child-bearing potential, participant is utilizing an acceptable&#xD;
             contraceptive method Participants must have access to, and the ability to use, â‰¥ 1&#xD;
             acute medication(s) (e.g., plasma-derived or recombinant C1- inhibitor (C1-INH)&#xD;
             concentrate or a bradykinin-2 [BK-2] antagonist) to treat angioedema attacks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Have any new condition or worsening of an existing condition or change or anticipated&#xD;
        change in medication, which in the opinion of the Investigator would make the participant&#xD;
        unsuitable for enrollment, or could interfere with the participant participating in or&#xD;
        completing the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical Research of Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIRE Medical of Los Angeles</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Immunology Clinical</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <zip>55446</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bernstein Clinical Research Center, LLC</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AARA Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 11, 2020</study_first_submitted>
  <study_first_submitted_qc>March 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2020</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hereditary Angioedema</keyword>
  <keyword>HAE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angioedema</mesh_term>
    <mesh_term>Angioedemas, Hereditary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

